FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
- Market Wrap: Markets Slump Amid Weak Econ. Data; GoDaddy Goes Public; U.S. Auto Sales Mixed in March
- McDonald's (MCD) Announces Enhanced Employee Benefits; Includes Wage Increase, Paid Vacation
- After-Hours Stock Movers 04/01: (RPRX) (TCPI) (XON) Higher; (SIGM) (CNAT) (MU) Lower (more...)
- Micron Technology (MU) Tops Q2 EPS by 8c
- Tesla (TSLA) Announces Model 'W'
The FDA approved Protalix's (NYSE: PLX) Gaucher Disease drug Elelyso
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dyax Corp (DYAX) Announces Positive Results from Phase 1b Trial of DX-2930 and Fast Track Designation
- Ocera Therapeutics (OCRX) Will Continue STOP-HE Study, Increase Enrollment on DMC Recommendation
- Baxter's (BAX) HOMECHOICE CLARIA Receives CE Mark
Create E-mail Alert Related CategoriesFDA, Hot FDA News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!